Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy (RT) with or without cisplatin in locally advanced head and neck squamous cell carcinoma (HNSCC).
V. Papadimitrakopoulou
Research Funding - AstraZeneca
J. Heymach
Consultant or Advisory Role - AstraZeneca; Auschon; Boehringer Ingelheim; GlaxoSmithKline; Pfizer
Research Funding - AstraZeneca; GlaxoSmithKline; Pfizer
S. J. Frank
No relevant relationships to disclose
J. Myers
No relevant relationships to disclose
H. Lin
Employment or Leadership Position - M.D. Anderson Cancer Center
H. T. Tran
No relevant relationships to disclose
C. Chen
Research Funding - AstraZeneca
F. R. Hirsch
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; OSI Pharmaceuticals; Roche/Genentech
Other Remuneration - Coinventor of University of Colorado owned patent: EGFR FISH as a predictive marker of EGFR inhibitors
P. B. Langmuir
Employment or Leadership Position - AstraZeneca
J. R. Vasselli
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
S. M. Lippman
No relevant relationships to disclose
D. Raben
Consultant or Advisory Role - Lilly